PsoroxAlternative Names: Exorias; Psorex
Latest Information Update: 26 Jun 2003
At a glance
- Originator Conpharm
- Class Antipsoriatics
- Mechanism of Action Microtubule protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Psoriasis
Most Recent Events
- 31 Dec 2001 Discontinued - Phase-III for Psoriasis in Sweden (Topical)
- 15 Dec 2000 Psorox is available for licensing
- 22 Sep 1997 Phase-III clinical trials for Psoriasis in Sweden (Topical)